Becton, Dickinson and Company (BDX) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Despite the decline in adjusted operating margin and EPS due to tariffs, the company shows strong revenue performance, operational execution, and a commitment to share buybacks. The Q&A reveals no structural changes hindering growth, strong momentum in key areas, and a stable pricing environment. However, uncertainties in China and vaccine headwinds persist. Positive elements like R&D investments and a stable pricing environment are offset by tariff impacts and cautious guidance, leading to a neutral sentiment.
Key Financial Performance
Revenue $5.3 billion, increased 0.4% year-over-year. Growth driven by 2.5% increase in New BD, with broad-based growth across markets, including double-digit growth in biologic drug delivery, PureWick, advanced tissue regeneration, and pharmacy automation. Partially offset by challenges in Alaris and vaccines in China.
Adjusted Gross Margin 53.4%, down 140 basis points year-over-year. Decline driven by approximately 170 basis points of tariffs, partially offset by productivity initiatives through BD Excellence.
Adjusted Operating Margin 21.2%, down 240 basis points year-over-year. Decline due to the impact of tariffs and increased commercial investments in key growth areas.
Adjusted EPS $2.91, down 15.2% year-over-year. Decline primarily driven by the impact of tariffs, but exceeded expectations due to strong revenue performance and operational execution.
Free Cash Flow $548 million, with a free cash flow conversion of 66%, improved from 59% in the prior year. Improvement driven by working capital discipline and capital efficiency.
Net Leverage 2.9x, with a commitment to a long-term net leverage target of 2.5x.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Biologic drug delivery: Achieved double-digit growth.
PureWick: Achieved double-digit growth.
Advanced tissue regeneration: Achieved double-digit growth.
Pharmacy automation: Achieved double-digit growth.
APM (Advanced Patient Monitoring): Achieved high single-digit growth.
Avitene Flowable: Launched in the U.S., entering a $400 million market growing at 5% annually.
Surgiphor: Launched in Europe, a ready-to-use wound irrigation system.
Surgiphor Pulse: Submitted to FDA, a pulse lavage system expanding BD's presence in a $200 million market by 40%.
HemoSphere Stream: Began targeted market release in the U.S. and Europe, with positive early feedback.
China market dynamics: Faced challenges in vaccines and other product categories, impacting growth.
U.S. market: Gained share in multiple categories, including flush, PICCs, and catheters.
GLP-1 molecules: Secured over 80 novel and biosimilar GLP-1 molecules contracted in BD delivery devices.
Manufacturing network: Reduced global sites by nearly half to under 50, lowering costs and improving resiliency.
Productivity improvements: Achieved 8% productivity improvements, contributing to gross margin and cash flow.
Cost-out program: Executed actions representing $150 million of the $200 million target, with clear line of sight to the balance.
Life Sciences transaction: Completed nearly 2 months ahead of schedule, receiving $4 billion cash distribution.
Capital allocation strategy: Deployed $2 billion for share repurchases and $2 billion for debt paydown.
Portfolio shaping: Divested three non-core assets and completed over 20 strategic tuck-ins to strengthen presence in high-growth healthcare areas.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Alaris, vaccines in China: Undergoing challenging market dynamics, which partially offset growth in other areas.
Volume-based procurement in China: Impacted performance in Medical Essentials and Specimen Management, leading to lower demand and tough comparisons to prior year.
Market dynamics in China: Affected multiple segments, including Specimen Management, Biopharma Systems, and Life Sciences, leading to revenue pressures.
Tariffs: Contributed to a 140 basis point decline in adjusted gross margin and a 240 basis point decline in adjusted operating margin.
Lower life science research funding: Pressured growth in the Biosciences segment.
U.S. point-of-care headwinds: Impacted Diagnostic Solutions performance.
Tough prior year comparisons: Created challenges in multiple segments, including Specimen Management and Diagnostic Solutions.
Increased commercial investments: Increased costs in key growth areas, impacting operating margins.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: For fiscal 2026, BD expects low single-digit revenue growth. Q2 revenue growth is projected at approximately 2%, consistent with the full-year guidance assumption.
Adjusted Operating Margin: BD expects an adjusted operating margin of about 25% for fiscal 2026, inclusive of the impact of tariffs.
Adjusted EPS Guidance: BD has established an adjusted EPS guidance range of $12.35 to $12.65 for fiscal 2026, reflecting growth of approximately 6% at the midpoint, including a 370 basis point impact from tariffs. Q2 adjusted EPS is expected to be in the range of $2.72 to $2.82.
Currency Impact: Currency is estimated to be a tailwind to revenue of about 120 basis points for fiscal 2026.
Capital Allocation: BD plans to deploy the $4 billion cash distribution from the Life Sciences transaction as follows: $2 billion for share repurchases through an ASR and $2 billion for debt paydown, subject to market conditions.
Operational Simplification: BD has reduced its manufacturing network by nearly half to under 50 global sites, lowering costs, improving resiliency, and enabling scaled smart factories.
Cost-Out Program: BD is executing a $200 million cost-out program, with actions representing $150 million already underway and clear line of sight to the remaining balance.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend Program: During the quarter, BD returned approximately $550 million to shareholders, including dividends.
Share Repurchase Program: BD announced a $2 billion allocation towards share repurchases through an Accelerated Share Repurchase (ASR) program as part of the $4 billion cash distribution received from the Life Sciences transaction. Additionally, $250 million in share buybacks were completed during the quarter.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the guidance for Q2 revenue and EPS, and how does it compare to the full year outlook?
A:Thomas Polen stated that the Q2 outlook reflects some modest timing benefits in Biopharma Systems and MMS seen in Q1. Adjusting for these, Q1 and Q2 are in line. There is no ramp from Q1 to Q2 or from the first half to the second half of the year, which is a better position compared to last year.
Q:Are there any structural changes in NewCo BD's categories that would affect the mid-single-digit growth rate?
A:Thomas Polen confirmed there are no structural changes that would preclude hitting the mid-single-digit growth rate. He highlighted the reshaping of the portfolio through divestitures and acquisitions, with 90% of the portfolio performing strongly. Investments in high-growth areas like PureWick, biologics, and pharmacy automation are on track and showing strong growth.
Q:What is the expected impact of China VBP, vaccine headwinds, and Alaris on the portfolio?
A:Thomas Polen stated that China VBP, vaccines, and Alaris are playing out as expected. China VBP is expected to impact 80% of the portfolio by the end of '26, with positive volume growth despite price compression. Vaccine headwinds will continue through '26 but will have a smaller impact in '27. Alaris showed strong competitive momentum with record new wins and share gains in Q1.
Q:Why is the Q2 growth rate set at 2% despite easier comps?
A:Vitor Roque explained that Q2 growth reflects slight timing changes in pharma systems and MMS. Normalizing for these, Q1 and Q2 growth are consistent. The guidance aligns with the full-year outlook, and there are no specific one-time factors affecting the 25% operating margin target.
Q:What is the outlook for GLP-1 franchise growth?
A:Thomas Polen confirmed the GLP-1 franchise is on track to reach $1 billion by the end of the decade. The franchise is nearing the halfway point, with over 80 novel and biosimilar GLP-1s contracted. Injectable GLP-1s continue to show strong momentum, and oral GLP-1s are seen as complementary.
Q:When will the R&D investments start showing results?
A:Thomas Polen stated that new product launches are happening this year, with significant launches planned for '27 and '28. Additional R&D programs have started in areas like tissue regeneration and biologic drug delivery. Efforts to accelerate innovation timelines are showing early success, with some projects accelerated by 6-12 months.
Q:What is the pricing environment and its impact on revenue growth?
A:Thomas Polen described the pricing environment as stable, with slight positive pricing outside China offset by China VBP. New product innovations are entering new markets, allowing for pricing aligned with delivered value. Pricing is expected to remain a positive factor as China VBP abates after '26.
Q:What is the outlook for Alaris beyond this year?
A:Thomas Polen stated that Alaris is expected to step up to a 200 basis point headwind in '27 due to remediation grow-over. However, the company expects to be in a stronger competitive position with record share levels. Innovation on the Alaris platform continues, with new features planned for submission later this year.
Q:What is the company's approach to M&A under the New BD strategy?
A:Thomas Polen emphasized a focus on tuck-in M&A rather than transformational deals. The criteria include being accretive to revenue growth and EPS. The company sees opportunities to supplement growth in high-growth sectors through focused M&A.
Q:What are the key drivers of potential upside to guidance?
A:Thomas Polen highlighted investments in high-growth areas like urinary incontinence, pharmacy automation, and biologics, as well as commercial excellence initiatives. The company is optimizing sales processes and compensation plans, which could drive higher growth.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the CFO search timeline and the exact share position of Alaris. Additionally, while they mentioned accelerating R&D timelines, they did not provide concrete examples of products or timelines for these innovations.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI informatics
AI patient
APM PI
ASR debt
Alaris vaccine
Alaris win
BD action
BD center
BD chapter
BD delivery
BD future
Connected Care
GLP
Medical Essentials
New BD
President Investor
Sciences transaction
Stream
Surgiphor
Systems
Waters
category
conversion
cost
disease
drug delivery
experience
health care
irrigation
moment
pharmacy
presence
priority
robotics
trend
tuck
work
BDX Transcript
Becton, Dickinson and Company (BDX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
Becton, Dickinson and Company (BDX) Q2 2026 Earnings Call Transcript
Unknown5-7
The earnings call presents a mixed picture. While there are positive elements like growth in medical essentials and connected care, strong cash flow, and confidence in future revenue and margin performance, there are concerns. The decline in biopharma systems, adjusted gross margin decrease, and lack of clarity on certain future projections temper optimism. The strategic focus on share repurchases and productivity improvements is positive, but headwinds from Alaris and China, and the temporary ship hold on ChloraPrep, introduce uncertainties. Overall, the sentiment is balanced, leading to a neutral stock price prediction.
Casey's General Stores, Inc. (CASY) Q3 2026 Earnings Call Transcript
Positive3-10
The strategic plan outlines positive initiatives such as share buybacks, innovation investments, and cost optimization, which are likely to bolster market sentiment. Despite challenges like tariff headwinds and revenue declines in specific segments, the company maintains stable margins and optimistic EPS growth. The Q&A insights reveal effective management of external factors and growth strategies, further supporting a positive outlook. These elements collectively suggest a positive stock price movement over the next two weeks.
Becton, Dickinson and Company (BDX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-10
BDX Slides
BDX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
